Compare Ascendis Pharma A/S (ASND) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Modine Manufacturing Company — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Modine Manufacturing Company trades at $241.73 (market cap $12.99B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Modine Manufacturing Company nearer its low. Which is the better fit depends on your goals.
| ASND | MOD | |
|---|---|---|
Market Cap | $17.74B | $12.99B |
Sector | Health | Technology |
52-Week High | $277.18 | $306.89 |
52-Week Low | $163.32 | $90.02 |
Enterprise Value | $18.11B | $13.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Modine (MOD) trades at $245.91, up 0.99% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong revenue growth to $2.58 billion in 2025, though net income margin compressed to 3.82%. Analyst consensus remains bullish with a $328.80 price target, supported by 10 buy ratings. Recent news highlights Modine's positioning in the AI data center cooling market, with sales projected to grow 60-80% in fiscal 2027.
The outlook is mixed: robust growth in data center demand offers upside, but high valuation multiples (P/E 108.81) and margin pressures pose risks. Investors face volatility from supply chain challenges and competitive threats in the HVAC segment. Wall Street optimism contrasts with technical weakness, suggesting cautious optimism for long-term growth despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
